Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Related Videos
View All
Related Content